The nanocomplex materials to be provided by PeptiMed will harbor motifs that bind to cell adhesion molecules on the surface of cancer cells and deliver an siRNA payload that silences the oncogene, EVI1. Initially, the NCL will assess the physical and chemical properties of the nanocomplexes followed by their purity and sterility in cell culture models. A second phase of testing for various modes of toxicity may be performed in animal models.
“We are profoundly pleased to work with the NCL to further our understanding of PeptiMed nanomaterials,” stated
PeptiMed co-founder Dr.
The mission of PeptiMed is to discover and provide nucleotide-based therapies and delivery systems for nucleotide-based drugs with unprecedented potency in ameliorating late-stage cancer while avoiding debilitating side effects, thereby improving prognosis and quality of life for each patient. PeptiMed has patented the hELPTM nanoparticle delivery system for nucleotides. PeptiMed plans to begin first-in-human studies to determine maximum tolerated and efficacious doses of the EVIRNATM/hELPTM nanocomplex by the end of FY2015.
This press release contains positive forward-looking statements concerning the therapeutic value of PeptiMed’s EVIRNATM/hELPTM nanocomplex. For further information please view the website www.peptimed.com or contactDr.
Chief Business Officer
Most Popular Stories
- 'Lucy's' Super Powers Tops 'Hercules' at Box Office
- The Rise and Fall of Richard Alarcon
- U.N. Renews Demand for Gaza Cease-Fire
- Nissan Profits Rise on Growth in U.S., China
- 'Sharknado' Sequel Has Bite and Lots of Laughs
- Vancrest Assisted Living Project to Add 20 Jobs
- The 2014 Fastest-Growing 100
- Pending Home Sales Slipped in June
- Shania Twain's Vegas residency ending after 110 shows
- Fighting Blocks Investigators, Police From MH17 Crash Site